Lifyorli (relacorilant)
Corcept Therapeutics (CORT)
ApprovedMar 25, 2026
Marketer take
A new option in platinum-resistant ovarian cancer after prior bevacizumab, and the same molecule faces a separate Cushing's syndrome decision on Dec 17, 2026, so watch for two brands with very different audiences.
- Sponsor company
- Corcept Therapeutics (CORT)
- Indication
- To treat platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior systemic treatment regimens, at least one of which included bevacizumab
- Therapeutic area
- Oncology
- Event
- FDA approval
- Date
- Mar 25, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?